In 2021, Medtronic stopped distributing the HVADs following studies that showed recipients had a higher risk of suffering strokes than those who were implanted with another company’s VAD. But Medtronic’s mission didn’t end with the suspension. In this episode, Raj Thomas, vice president and general manager of MCS, explains how his team continues to support recipients, their caregivers and clinicians to help ensure those heart failure patients can live the fullest lives possible.